Sukhmani K. Padda was named director of Thoracic Medical Oncology at Cedars-Sinai Cancer.
Padda’s research focuses on therapies for thoracic cancers, with a particular interest in improving treatment for genomic subsets of lung cancer, including KRAS- and EGFR-positive lung cancer, and rare thoracic tumors, such as thymic malignancies and lung neuroendocrine tumors.
She also studies questions related to tumor biomarkers to help determine the best treatments for patients.
By law, the Food and Drug Administration is required to determine whether a drug, device, biologic, or medical device is “safe and effective.” But the FDA determination does not control whether the Centers for Medicare & Medicaid Services will pay for it. To satisfy CMS, medical products and services must be “reasonable and necessary,” meaning...
As a radiation oncologist, I am struck by how often the decisive variable in lung cancer is not the sophistication of our therapy, but the timing of our encounter with the disease. The American Cancer Society projects 618,120 cancer deaths in the United States in 2025, with lung cancer remaining as the single largest contributor,...
